Design, synthesis, and pharmacological evaluation of fluorinated azoles as anti-tubercular agents. 2018

Somnath Gholap, and Macchindra Tambe, and Laxman Nawale, and Dhiman Sarkar, and Jaiprakash Sangshetti, and Manoj Damale
Postgraduate Department of Chemistry and Research Centre, Padmashri Vikhe Patil College, Pravaranagar, A/P-Loni kd, Tal.-Rahata, Ahmadnagar, India.

Design, synthesis, and biological screening of 2,2-dimethyl-2,3-dihydrobenzofuran tethered 1,3,4-oxadiazole derivatives as anti-tubercular agents were described. The synthesis of the target compounds was conducted by a series of reaction schemes. All the synthesized compounds were characterized by IR, 1 H NMR, 13 C NMR, and mass spectrometry. The therapeutic potential of the synthesized compounds was confirmed by molecular docking studies. Among the synthesized compounds, 12a, 12c, 12d, 12e, 12g, and 12j were found to be more active against non-replicating than against replicating cultures of Mycobacterium tuberculosis H37Ra ex vivo and in vitro. These compounds exhibit minimum inhibitory concentration (MIC) values in the range of 2.31-23.91 μg/mL. The cytotoxicity study was conducted against the cell lines THP-1, A549 and PANC-1, and the compounds were observed to be non-toxic to host cells. Molecular docking was conducted with InhA (FabI/ENR) and suggested the antimycobacterial potential of the synthesized compounds. The investigation presented here was found to be adventitious for the development of new therapeutic agents against Mycobacterium infection.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D009164 Mycobacterium Infections Infections with bacteria of the genus MYCOBACTERIUM. Infections, Mycobacterium,Infection, Mycobacterium,Mycobacterium Infection
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000995 Antitubercular Agents Drugs used in the treatment of tuberculosis. They are divided into two main classes: "first-line" agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and "second-line" drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy. Anti-Tuberculosis Agent,Anti-Tuberculosis Agents,Anti-Tuberculosis Drug,Anti-Tuberculosis Drugs,Antitubercular Agent,Antitubercular Drug,Tuberculostatic Agent,Tuberculostatic Agents,Antitubercular Drugs,Agent, Anti-Tuberculosis,Agent, Antitubercular,Agent, Tuberculostatic,Anti Tuberculosis Agent,Anti Tuberculosis Agents,Anti Tuberculosis Drug,Anti Tuberculosis Drugs,Drug, Anti-Tuberculosis,Drug, Antitubercular
D001393 Azoles Five membered rings containing a NITROGEN atom. Azole
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Somnath Gholap, and Macchindra Tambe, and Laxman Nawale, and Dhiman Sarkar, and Jaiprakash Sangshetti, and Manoj Damale
November 2015, European journal of medicinal chemistry,
Somnath Gholap, and Macchindra Tambe, and Laxman Nawale, and Dhiman Sarkar, and Jaiprakash Sangshetti, and Manoj Damale
February 2020, RSC advances,
Somnath Gholap, and Macchindra Tambe, and Laxman Nawale, and Dhiman Sarkar, and Jaiprakash Sangshetti, and Manoj Damale
January 2014, Iranian journal of pharmaceutical research : IJPR,
Somnath Gholap, and Macchindra Tambe, and Laxman Nawale, and Dhiman Sarkar, and Jaiprakash Sangshetti, and Manoj Damale
January 2013, Chemical & pharmaceutical bulletin,
Somnath Gholap, and Macchindra Tambe, and Laxman Nawale, and Dhiman Sarkar, and Jaiprakash Sangshetti, and Manoj Damale
November 2021, Molecular diversity,
Somnath Gholap, and Macchindra Tambe, and Laxman Nawale, and Dhiman Sarkar, and Jaiprakash Sangshetti, and Manoj Damale
August 2017, Bioorganic & medicinal chemistry,
Somnath Gholap, and Macchindra Tambe, and Laxman Nawale, and Dhiman Sarkar, and Jaiprakash Sangshetti, and Manoj Damale
October 2016, Chemical biology & drug design,
Somnath Gholap, and Macchindra Tambe, and Laxman Nawale, and Dhiman Sarkar, and Jaiprakash Sangshetti, and Manoj Damale
May 2019, Bioorganic chemistry,
Somnath Gholap, and Macchindra Tambe, and Laxman Nawale, and Dhiman Sarkar, and Jaiprakash Sangshetti, and Manoj Damale
September 2022, ACS applied bio materials,
Somnath Gholap, and Macchindra Tambe, and Laxman Nawale, and Dhiman Sarkar, and Jaiprakash Sangshetti, and Manoj Damale
January 2016, PloS one,
Copied contents to your clipboard!